Lianxi Liao, MD
Cardiovascular Disease · Fort Worth, TXNPI 1043296502
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.0% of the total across 302 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 20.0% — the pattern of someone who eats at a lot of different presentations.
Across 302 payments — averaging $18.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1K
- AstraZeneca$730
- Johnson & Johnson$664
- Pfizer$480
- Sanofi-aventis U.S. LLC$408
- Merck$403
- plus $2K from 20 others
Across 71 payments — averaging $1585.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Argenx US, Inc.$113K
What the payments were for
- Food & beverage$5,43895%
- Education$2835%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 55 | $1,142 |
| AstraZeneca | 42 | $730 |
| Johnson & Johnson | 42 | $664 |
| Pfizer | 26 | $480 |
| Sanofi-aventis U.S. LLC | 22 | $408 |
| Merck | 26 | $403 |
| Boehringer Ingelheim | 14 | $325 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 19 | $317 |
| Astellas Pharma US Inc | 2 | $155 |
| E.r. Squibb & Sons, L.L.C. | 8 | $151 |
| Actelion Pharmaceuticals US, Inc. | 2 | $120 |
| Scpharmaceuticals Inc. | 6 | $111 |
| Amarin Pharma, Inc. | 6 | $98 |
| Arbor Pharmaceuticals, Inc. | 7 | $94 |
| GE HealthCare | 3 | $91 |
| Lexicon Pharmaceuticals, Inc. | 4 | $75 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $74 |
| Esperion Therapeutics, Inc. | 4 | $70 |
| Amgen | 3 | $53 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $47 |
| Boston Scientific | 1 | $27 |
| Teleflex LLC | 1 | $22 |
| Bayer | 1 | $20 |
| Kestra Medical Technology Services, Inc. | 1 | $15 |
| Chiesi USA, Inc. | 1 | $15 |
| Abbott | 1 | $15 |
How this compares
$5,721 in reported general payments places this provider in the 60th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 228 | $248,306 |
| XareltoRivaroxaban | 73 | $92,005 |
| MultaqDronedarone Hcl | 28 | $38,186 |
| EntrestoSacubitril/Valsartan | 27 | $31,299 |
| Repatha SureclickEvolocumab | 27 | $17,588 |
| FarxigaDapagliflozin Propanediol | 27 | $16,847 |
| BrilintaTicagrelor | 15 | $8,371 |
| Metoprolol Succinate | 208 | $2,634 |
| Flecainide Acetate | 22 | $1,458 |
| Clonidine | 11 | $1,361 |
| Chlorthalidone | 72 | $1,338 |
| Atorvastatin Calcium | 91 | $1,308 |
| Propafenone Hcl | 25 | $1,176 |
| Rosuvastatin Calcium | 90 | $1,137 |
| Labetalol Hcl | 42 | $1,114 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $480 | $248,306228 claims |
| Johnson & JohnsonXarelto | $664 | $92,00573 claims |
| Sanofi-aventis U.S. LLCMultaq | $408 | $38,18628 claims |
| NovartisEntresto | $1,142 | $31,29927 claims |
| AstraZenecaFarxiga, Brilinta | $730 | $25,21742 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,515 cardiovascular disease providers in Texas.
Other cardiovascular disease in Fort Worth
- Ramin Farzaneh-FarDallas$17.1M
- John OsborneGrapevine$1.3M
- Darren McGuireDallas$1.2M
- Peter McCulloughDallas$664K
- Ann NavarDallas$616K
- Biykem BozkurtHouston$606K
- Milton PackerDallas$530K
- Amarinder BindraDallas$512K
- Robert SalazarKingwood$478K
- Reynolds DelgadoHouston$471K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.